Daily Aspirin Treatment After Preeclampsia

Description

Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.

Conditions

Preeclampsia

Study Overview

Study Details

Study overview

Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.

Aspirin for the Treatment of Vascular Dysfunction After Preeclampsia

Daily Aspirin Treatment After Preeclampsia

Condition
Preeclampsia
Intervention / Treatment

-

Contacts and Locations

Iowa City

University of Iowa, Iowa City, Iowa, United States, 52242

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * had preeclampsia in the past 5 years,
  • * 18 years or older
  • * current daily aspirin use,
  • * skin diseases,
  • * current tobacco or nicotine use (including vaping),
  • * diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR \< 60 mL/min/1.73m2,
  • * statin or other cholesterol-lowering medication,
  • * current antihypertensive medication,
  • * history of hypertension prior to pregnancy,
  • * history of gestational diabetes,
  • * currently pregnancy,
  • * body mass index \<18.5 kg/m2,
  • * allergy to materials used during the experiment.(e.g. latex),
  • * known allergies to study drugs,
  • * bleeding disorders, peptic ulcer disease, gastritis, GI bleeding and gastroesophageal reflux disease (GERD).

Ages Eligible for Study

18 Years to 50 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Anna Stanhewicz, PhD,

Study Record Dates

2026-02